Side-by-side · Research reference
CartalaxvsPE 22-28
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-StrongHUMAN-REVIEWED16/47 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
PE 22-28
TREK-1 Antagonist · Pre-Clinical
IP · SQ · Once Daily (animal models)Djillani 2017Pietri 2019
01Mechanism of Action
Parameter
Cartalax
PE 22-28
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
TREK-1 two-pore-domain potassium channelDjillani 2017Ma 2020
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
TREK-1 channel blockade → Neuronal membrane depolarisation → Enhanced hippocampal excitability → Increased neuroplasticity
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Antidepressant-like activity in forced swim test and tail suspension test; reduced A1-like reactive astrocyte activation; neuroprotection via NF-κB pathway modulationDjillani 2017Cong 2023Wu 2021
Feedback intact?
—
N/A — direct ion channel blockade; not receptor-mediated endocrine axis
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Synthetic truncation of spadin (PE 12-28), itself derived from the sortilin propeptide C-terminus. Residues 22-28: Val-Val-Arg-Gly-Trp-Leu-Arg.Djillani 2017Mazella 2018
Antibody development
—
Not reported in animal studies
02Dosage Protocols
Parameter
Cartalax
PE 22-28
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
Multiple rodent RCTs; behavioral + electrophysiology endpointsDjillani 2017Qi 2018Wu 2021
Animal dose (antidepressant)
—
0.3–3 µg/kg IP
Effective in forced swim test, tail suspension test, CUMS models.
Animal dose (neuroprotection)
—
0.03 µg/kg IPPietri 2019
Low-dose TREK-1 activation post-stroke for 7 days, then high-dose blockade.
Frequency
—
Once daily
Sustained antidepressant effect over 7+ days.
Onset (animal)
—
Within hours (acute); full effect 4–7 days
Comparison to fluoxetine
—
PE 22-28 outperforms fluoxetine in CUMS-sensitive rats by day 7
Chronic administration shows superior long-term efficacy.
Human equivalent (extrapolated)
—
Not established — no clinical trials
Allometric scaling from rodent data unavailable.
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
PE 22-28
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
PE 22-28
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Toxicity (animal)
—
No adverse effects reported at therapeutic doses
Cardiovascular (theoretical)
—
TREK-1 expressed in cardiac tissue; arrhythmia risk unclear
Weight change
—
Not reported in animal studies
Neurological
—
No seizures or behavioral abnormalities noted
Long-term safety
—
Unknown — longest animal study 28 days
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
PE 22-28
- ·Human use — no clinical safety data available
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
PE 22-28
- ·Cardiac arrhythmia or channelopathy (theoretical TREK-1 cardiac role)
05Administration Protocol
Parameter
Cartalax
PE 22-28
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Dissolved in sterile saline or vehicle. Intraperitoneal injection, 0.3–3 µg/kg body weight. Once daily administration in rodent behavioral studies.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Shorter peptide length (7 AA) confers improved plasma stability vs 17-AA spadin. Exact storage conditions not detailed in published protocols.Djillani 2017
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Enhanced CNS bioavailability vs full spadin, likely due to smaller size. Mechanism (passive diffusion vs active transport) not fully characterized.
4. Human formulation
—
Not established — peptide synthesis methods for research use only. No pharmaceutical-grade formulation available.